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THYMIC NEUROENDOCRINE 
CARCINOMA (CARCINOID): 
A CLINICOPATHOLOGIC 
STUDY OF FOURTEEN 
CASES 
The medical records and histologic documents of 14 patients treated at our 
institution for a thymic carcinoid tumor were reviewed. There were 3 women 
and 11 men with an age range from 35 to 71 years. One patient had a 
multiple endocrine neoplasia syndrome; another had a neurofibromatosis. 
Twelve tumors were revealed by Iocal symptoms and two were asymptom- 
atic. One patient had Cushing's syndrome that appeared secondarily and 
was related to metastases. Tumors ranged from 6 to 20 cm and had the 
characteristie histologic appearance of atypical carcinoid tumor. Immuno- 
histochemical evaluations were done. Tumors were positive for cytokeratin 
(92%), neuroendocrine markers (100%), and p53 oncoprotein (29%). S-100 
protein antibody revealed numerous sustentacular cells in one case. Overall 
survival was 46% and 31% at 3 and 5 years, respectively. However, all 
patients died of the disease within 109 months as a result of local 
progression (n = 5), loeal relapse (n = 3), distant metastases (n = 8), or a 
combination of these reasons. Median survival was 71, 30, and 5 months for 
patients who had total resection (n = 4), partial resection (n = 5), or simple 
biopsy (n = 4), respectively (p = 0.023). In eonclusion, thymic earcinoid 
tumors can be considered thymic neuroendoerine carcinomas because of 
their malignant behavior and histologic appearance of atypical carcinoid 
tumors. Complete surgical resection offers the best hope for long-term 
survival. (J TrIORAC CARDIOVASC SURG 1996;111:134-41) 
Vincent Thomas de Montpréville, MD, ~ Paolo Macchiarini, MD, b and 
Elisabeth Dulmet, MD, a Le Plessis-Robinson, France 
M ediastinal or thymic carcinoid tumors are ex- 
tremely rare and only a few small series have 
been reported in the literature. 1-7 Among malignant 
epithelial tumors o f  the thymus, these carcinoid 
tumors are presently sharply separated not only 
from thymomas but also from thymic carcinomas, s' 9 
To provide more diagnostic, prognostic, and histo- 
logic data about this unusual neoplasm and to 
discuss the nosologic features of thymic carcinoid 
tumors and their relations with thymic carcinomas, 
we present he cases of 14 patients who underwent 
operation at our institution. 
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Material  and methods 
Between 1960 and 1990, 17 patients underwent opera- 
tion for a mediastinal carcinoid tumor at our institution. 
Clinical data were obtained from patients' records and 
follow-up information from the referring physician. Three 
cases were excluded from this study; two were considered 
metastatic lesions from an associated large bronchial 
atypical carcinoid tumor and a pancreatic neuroendocrine 
carcinoma. A third case was excluded because of insuffi- 
cient histologic material. The 14 remaining cases, which 
form the basis of the current study, presented as primary 
mediastinal neoplasms. A primary lung tumor was ruled 
out by bronchoscopy (n = 8) and radiographs, tomo- 
graphs, or computed tomographic scan of the chest. 
Tumor size was determined from the surgical specimen 
or, when the tumor was not resected, from imaging studies 
of the chest. Tumor location was assessed from these 
imaging studies and from surgical report. 
Tissue for light microscopy and immunochemistry was 
flxed in buffered 10% formaldehyde and embedded in 
paraffin. All cases were stained with hematoxylin and 
eosin and Grimelius stains. A mean of five paraffin blocks 
was available for each case. Atypical carcinoid tumor was 
defined according to the criteria used for bronchopulmo- 
nary neuroendocrine tumors, l° Immunohistochemical 
study was done with LSAB Kit peroxidase (Dako, 
Trappes, France). The following primary antibodies were 
used with the indicated dilutions: rabbit anti-human 
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Tab le  I. [nitial clinical and radiologic features, treatment, and fo l low-up 
Patient Age, First symptom, Clinical findings Tumor size (cm) Initial Postoperative Relapse Total survival 
no. sex duration at diagnosis and location operat ion treatment and metastasis after diagnosis 
1 53, M Chest pain, Normal 7 × 5.5 × 3, Total Tx No Local R at 25 mo 79 mo with 
6 mo sup., ant., and left treated by progression 
RT and CT of local R 
66, M None Local R at 68 mo 71 mo 2 Normal 12 × 10 × 6, sup., Total Tx RT (60 Gy) 
ant., and left 
3 71, M Pain, cough, Normal 13 Ó, sup., ant., Subtotal Tx RT and CT 
5 mo and left 
4 54, M Dyspnea, Severe dyspnea, 20 qS, all ant. me- Debulking RT 
6 mo asthenia diastinum 
5 49, F None Normal 6 × 4 × 4, middle Total Tx No 
mediastinum and 5 mm 
lung Mx 
O 56, F Chest pain, Dyspnea, left RP, 7 4~, middle medi- Biopsy No (refused) 
3 mo asthenia astinum 
7 55, M Not known SVC syndrome, Not known,* ant. Biopsy Symptomatic 
pleural effusion and sup. 
8 39, M Chest pain, Weight loss 12 O, all sup. me- Biopsy RT 
1 yr diastinum 
9 58, M Pain, dyspnea, Asthenia, dyspnea 10 × 10 × 6, ant. Subtotal Tx RT (50 Gy) 
5 mo and sup. and CT 
10 38, M Chest pain, Dyspnea, weight 10 Ó, ant. and Subtotal Tx Not known 
1 yr loss sup. 
11 35, M Chest pain, SVC syndrome, 8 × 7 × 4, ant. Subtotal Tx RT? and CT 
3 mo dysphonia and sup. 
12 08, M SVC syn- SVC syndrome 8 × 7 x 3, ant., Total Tx RT (O0 Gy) 
drome, 2 sup., and left 
mo 
13 47, M Dysphonia, Left RP, SVC 8 qS, ant. and sup. Biopsy (cer- Not known 
1 yr syndrome, sub- vical LN 
clavicular mass met.) 
14 55, M Chest pain, SVC syndrome, 10.5 × 9.5 × 9, Biopsy RT (40 Gy) 
1 mo dysphonia ant., sup., and left and CT 
Symptomatic 56 mo, suicide, 
treatment for progression 
vertebral met. of met. 
at 49 mo 
Local progression ó mo 
Vertebral Mx at 109 mo with 
60 mo, brain new brain 
Mx at 84 mo met. 
Not known Not known 
Local progression 1 mo 
Osseous and 
brain met. 
Left pleural car- 
cinosis at 
16 mo 
CT for local R 
and lung Mx 
at 14 mo 
CT for cervical 
LN met. at 
30 mo 
RT for cervical 
LN and verte- 
bral met. at 
18 mo 
Not known 
5 mo 
20 mo 
64 mo with 
dissemi- 
nated dis- 
ease 
40 mo with 
progression 
of LN mer. 
36 mo with 
Cushing's 
syndrome 
10 mo 
Local progression 14 mo 
M, Male; F, female; sup., superior; ant., anterior; Tx, tumor esection; R, relapse; RT, radiation therapy; CT, chemotherapy; mer., metastasis; Mx, metastasis 
resection; RP, recurrent paralysis; SVC, superior vena cava; LN, lymph node. 
*Massive right pleural effusion. 
t40 Gy before operation and 20 Gy after operation. 
neuron-specific enolase (Dako, 1/50), monoclonal  mouse 
ant i -human chromogranin A (Dako, 1/40), rabbit anti-cow 
S-100 (Dako, 1/200), monoclonal  mouse antikeratin (KL1, 
Dako 1/50), monoclonal  mouse ant i -human p53 protein 
(Dako, 1/25), monoclonal  mouse ant i -human macrophage 
CD68 (KP1, Dako, 1/50), rabbit anti-synthetic human 
adrenocort icotropic hormone (ACTH) 1-24 (Dako, 
1/200), rabbit ant i -bombesin (Euromedex, Schiltigheim, 
France, 1/1000), polyclonal rabbit anti-glucagon (Unipath, 
Dardilly, France; prediluted), rabbit anti-insulin (Uni- 
path, prediluted), rabbit anti-pancreatic polypeptide 
(Unipath, prediluted), and rabbit anti-somatostatin 
(Unipath, prediluted). Normal  pancreas was used as pos- 
itive control for insulin, glucagon, pancreatic polypeptide, 
and somatostatin. Normal pituitary gland was used as 
positive control for ACTH and fetal lung was used for 
bombesin. 
For statistical analysis, survival was calculated from the 
date of operat ion until death estimated with the product- 
limit method, and differences on its distribution were 
calculated with the log-rank test, 
Results 
Clinical and radiologic findings. Se lected  data  at 
p resentat ion  are summar ized  in Tab le  I. Pa t ient  8 
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Fig. 1. Survival curve of thymic arcinoid tumors: overall 
survival. 
had a von Recklinghausen's disease with "café au 
lait" spots and multiple thoracic dermal neurofibro- 
mas: symptoms similar to those of the male parent. 
He had no evidence of gastrointestinal tumor. Pa- 
tient 5 had multiple endocrine neoplasia (MEN) 
syndrome. This patient's brother had Zollinger- 
Ellison syndrome; she herself was treated for a 
parathyroid adenoma 6 years after diagnosis of the 
mediastinal carcinoid tumor. Patient 7 had a severe 
chronic psychosis. At presentation, none of the 
patients had manifestations of abnormal secretion. 
In particular, none had carcinoid syndrome. Five 
patients were heavy smokers. All patients had ab- 
normal findings on chest roentgenograms, and to- 
mograms or computed tomographic scans specified 
size and location of the tumor. A bronchoscopy was 
done in eight cases and showed normal findings in 
two. In the six others, bronchoscopy revealed an 
extrinsic compression of trachea or major bronchi. 
Tracheobronchial biopsy provided no tumoral ma- 
terial. 
Laboratory findings. Serum carcinoembryonic 
antigen level was normal in six cases and elevated in 
case 8 (24 ng/L, normal <5). Calcium level was 
normal in 11 cases. The patient with MEN syndrome 
had hypercalcemia (2.7 mmol/L, normal <2.6) with 
elevated alkaline phosphatase l vels (166 IU/L, nor- 
mal <90). These abnorrnalities were probably re- 
lated to the parathyroid adenoma later discovered. 
Patient 10 also had hypercalcemia (3.16 mmol/L, 
normal <2.6) but normal alkaline phosphatase l v- 
els. No patient underwent further investigation i  
the search for hyperparathyroidism at that time. 
Serum ionic concentrations were normal in all cases 
and no patient had hypokalemia that could 
indicate a possible hypercortisolism. Urinary 5-OH- 
indoleacetic acid value was normal in the three 
tested cases. The patient with neurofibromatosis 
had a normal urinary vanillylmandelic a id level (20 
Bmol in 24 hours, normal <30). 
Treatment and follow-up data (Table I). Tu- 
moral resections were orten extended to invaded 
adjacent structures: pericardium in five cases, lung 
(wedge resection) in two cases, innominate rein in 
one case, and vena cava in two cases. Invaded 
thymus could be identified in three cases. Subtotal 
resection was done in four cases in which tumoral 
tissue was left by one phrenic nerve when the two 
were iuvaded (3 cases), in the trachea (1 case), in the 
left carotid artery (1 case), and in the subclavian 
artery (1 case). Adjuvant reatments were not stan- 
dardized. Three years after initial diagnosis, Cush- 
ing's syndrome developed in patient 12 with high 
and irregular ACTH serum levels. There was no sign 
of mediastinal tumoral relapse and Cushing's yn- 
drome was related to a T12 vertebral metastasis. 
Overall survival was 46% and 31% at 3 and 5 years, 
respectively; however, all patients died of the dis- 
ease within 109 months with a median survival of 28 
months (Fig. 1). Death was related to local progres- 
sion (5 cases), local relapse (3 cases), and distant 
metastases (8 cases). Median survival was 71, 30, 
and 5 months for patients who had total resection 
(n = 4), partial resection (n = 5), or simple biopsy 
(n = 4), respectively (/9 = 0.023) (Fig. 2). 
Pathologic findings. All tumors demonstrated 
the characteristic neuroendocrine architecture of 
carcinoid tumors, orten with palisading or rosette 
patterns. In 12 cases, the tumor contained irregular 
areas of necrosis, sometimes with foci of dystrophic 
calcification. The stroma was usually scant and 
fibrovascular, hut in six cases it was focally fibrous 
and in case 11 (treated by radiation) the tumor had 
a dense hyalin fibrous stroma (Fig. 3). Tumoral cells 
were of large size and regular. Their nucleus was 
oval to round with finely granular chromatin. Cyto- 
plasm was eosinophilic or pale. These cells had a 
polygonal shape hut were fusiform in case 5 associ- 
ated with MEN syndrome (Fig. 4) and in a small 
area in case 2. There was no small cell component. 
Mitotic figures could be observed in all cases but 
were never greater than 10 per 10 high-power fields 
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Fig. 2. Survival curve of thymic carcinoid tumors: survival according to type of operation (p = 0.023). 
Fig. 3. Case 11. Nonsterilized thymic carcinoid tumor displaying abundant hyalin fibrous troma after 
pre0perative radiation therapy. 
(Fig. 4). Because of necrosis and mitotic activity, all 
cases were~ classified as atypical carcinoid tumors. 
Tumors were partially encapsulated. A pseudo- 
capsule was sometimes identified as a thickened 
fibrous mediastinal pleura. Tumoral infiltration of 
adipose tissue was observed in 5 of the 10 resection 
specimens and was associated with tumoral lym- 
phangitis in two cases. 
Histochemical and imnmnohistochemical find- 
ings (Table II). All tumors expressed at least two of 
the three neuroendocrine markers used in this eval- 
uation. In case 3, anti-S-100 protein antibody re- 
vealed numerous cells with morphologic features of 
the sustentacular cells seen in paraganglioma (Fig. 
5). These cells did not express the CD68 histiocytic 
marker. Otherwise, tumoral cells were S-100 protein 
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Fig. 4. Case 5 (associated with MEN syndrome). Thymic carcinoid tumor made up of spindle cells. This 
morphologic appearance can be confused with that of spindle cell thymoma, but lack of lymphoid 
comp0nent and immunohistochemical d ta permitted iagnosis. Mitotic feature is indicated with arrow. 
Table II. Grirnelius stain and 
immunohistochemical findings 
Case 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Gr imel ius  - + 
Cytokerat in  + + 
NSE + + 
Chromogran in  + + 
Prote in  S-100 
p53 + - - - 
- + - -  + + + + + - + 
+ + + -- + nd + + + + + + 
+ + + + + + + + + + + + 
- + + + - - + - + + 
+* 
+ + + 
nd, Not done; NSE, neuron-specific enoläse. 
*Sustentacular cells. 
negative in all cases. Cytokeratin was strongly ex- 
pressed in l0 cases including the one with sustentacu- 
lar cells, weakly in case 12, and focally in case 5 with 
fusiform cells. Antibody to p53 stained strongly most 
of the tumoral cell nuclei n case 7 and weakly few of 
these nuclei n three other cases. No secretion product 
was detected by immunohistochemistry. In the patient 
in whom Cushing's yndrome later developed, testing 
for ACTH was negative in the primitive tumor. 
Diseussion 
The observations made in this study provide 
evidence that thymic carcinoid tumors (1) may 
present with a variety of clinical onsets, (2) behave 
as malignant tumors, (3) have a prognosis related to 
the radicalness of the surgical resection, and (4) 
have a distinctive histologic and immunohistologic 
appearance. These neoplasms can either be asymp- 
tomatic, associated with symptoms related to local 
growth, or part of a MEN syndrome and can pro- 
duce endocrinopathy, 1-9 especially Cushing's syn- 
drome.il, 12 The peculiarity of our case with Cush- 
ing's syndrome was that the endocrinopathy was not 
present at the time of diagnosis and appeared only 
in the late phase of the disease. MEN syndrome 
often comprises hyperparathyroidism, as in our 
case. 13 A tumor developed in one of our patients in 
association with neurofibromatosis, another sys- 
temic disease involving the neuroendocrine system. 
This is an unusual event because in this condition, 
carcinoid tumors are rare and almost exclusively 
gastrointestinal.14 
Our study confirms the malignant behavior and 
the poor prognosis of thymic carcinoid tumors. In 
three previously published series, 4 of 7, 5 7 of 8, 6 and 
5 of 87 cases were reported as having locally invasive 
lesions and only 4 of our 14 cases could be totally 
resected. Relapse occurred in 3 of out 8 patients 
who underwent surgical resection. Distant metasta- 
ses occurred in 7 of our patients and in 11 of 15, 2 11 
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Fig. 5. Case 3. Sustentacular cells revealed by anti-S-100 protein in thymic carcinoid tumor. 
of 12, 3 and 7 of 86 patients in three other series. 
Only ó of 44 cases from four series, 2' 5, 7 including 
ours, have had a protracted course with a survival of 
more than 8 years. Median survival of 28 months in 
our series is in line with that reported by others. 2' 5 
Operation is the most effective treatment 5 and com- 
plete resection offers the best hope for long-term 
survival. 
Histologic diagnosis of mediastinal carcinoid tu- 
mor is fac~litated by recognition of its characteristic 
morphologic features. Areas of necrosis, sometimes 
calcified, are usual features. 90ur  case with hyalin 
fibrous stroma was interesting in that the tumor had 
been radiated with 40 Gy and was absolutely not 
sterilized. In the current series and in our recent 
study of 98 mediastinal germ cell tumors, ~5 we did 
not encounter carcinoid tumors arising in a germ 
cell neoplasrn like the one previously reported. 16 
Our case with sustentacular cells is a variant not 
previously reported. Such "paraganglioid" tumors 
generally ~ccount for a variable percentage of bron- 
chial and gastrointestinal carcinoid tumors and have 
no other relevant biologic significanceJ 7 ACTH is 
the neuropeptide most commonly detected in thy- 
mic carcinoid tumors, 2 but other secretory products, 
which do not usually correspond to manifestation f
clinical symptoms, 4 have also been detected. 3' 40ur  
immunohistochemical neuropeptide search had 
negative results. The p53 nuclear oncoprotein was 
detected in 45% of 22 pulmonary atypical carcinoid 
tumors but not in any of 15 typical carcinoids, is In 
our current series, 4 (29%) of 14 tumors were found 
to express p53. This expression had no prognostic 
value because two of these patients had a rapid fatal 
outcome and another had the longest survival. 
The thymus is considered the principal origin for 
primary mediastinal carcinoid tumors. 9 These thy- 
mic tumors can be differentiated from other medi- 
astinal neuroendocrine neoplasms. 19A metastasis 
especially from a bronchopulmonary carcinoid tu- 
mor must be clinically formally excluded. Mediasti- 
nal parathyroid adenomas are not exceptional, t9 but 
only the rare and exceptionally nonsecreting medi- 
astinal parathyroid carcinoma can be considered in 
the differential diagnosis of thymic carcinoid tumor 
with malignant behavior. Mediastinal paragangli- 
oma 2° theoretically can bedistinguished from carci- 
noid tumors by its constant lack of immunoreactivity 
for cytokeratin. Nonneuroendocrine mediastinal 
neoplasms, which can histologically be confused 
with carcinoid tumors, are infrequent hymomas 
without any lymphoid component. Immunohisto- 
chemical negativity for neuroendocrine markers can 
permit diagnosis. 
Our study confirms that thymic carcinoid tumors 
represent a specific entity. This entity is usually 
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separated from the other malignant epithelial thy- 
mic tumors, namely, thymomas and thymic carcino- 
mas. However, several elements uggest that thymic 
carcinoid tumors may be compared with the group 
of thymic carcinomas. This comparison is based on 
the following observations. First, thymic carcinomas 
are rare and not associated with immunologic dis- 
orders such as myasthenia gravis. These carcinomas 
have a propensity to produce lymph-node and ex- 
trathoracic metastases. 21-23 Such clinical features 
are shared with thymic carcinoid tumors and clearly 
distinguish these tumors from the more common 
and less aggressive thymomas. Furthermore, the 
prognosis in patients with thymic carcinoid tumors is 
close to the survival rate (33.3% at 5 years) reported 
for thymic carcinomas) 2 Second, all our 14 cases 
and all the 8 cases in a recent detailed pathologic 
series 7 were considered atypical carcinoid tumors. 
Typical carcinoid tumors of the thymus are excep- 
tional. 7 In the lung, the term atypical carcinoid tumor 
is used as synonymous with well-differentiated neu- 
roendocrine carcinoma] ° The term carcinoma is 
suitable for thymic carcinoid tumors and is a better 
term to indicate an epithelial neoplasm with malig- 
naht behavior than carcinoid, which in some loca- 
tions such as lung 1° corresponds to a benign or a low 
aggressive tumor. Third, there is no histologic evi- 
dence to exclude a well-differentiated neuroendo- 
crine carcinoma in the heterogeneous group of 
thymic carcinomas. Obvious features of cytologic 
atypia are usually required for this diagnosis 21 but 
several thymic carcinomas, uch as mucoepidermoid 
carcinoma, are of a low-grade histologic type. = The 
group of thymic carcinomas also includes small cell 
carcinoma, 22 which is another neuroendocrine o- 
plasm. Fourth, recognition of a carcinoid compo- 
nent in rare thymic carcinomas confirms a link 
between these two entities. 24' 25 
In light of these arguments, inclusion of thymic 
carcinoid tumors in the group of thymic carcinomas, 
as has already been suggested by a recent surgical 
series of thymic carcinomas including two carcinoid 
tumors, 23 appears justified. Therefore a thymic car- 
cinoid tumor should be considered, as has already 
been proposed, a thymic carcinoma of a carcinoid 
type 26 or, rather, as a thymic well-differentiated 
neuroendocrine carcinoma. This would permit a 
more comprehensive classification of malignant thy- 
mic epithelial neoplasm by distinguishing all thymic 
carcinomas (neuroendocrine and others) from thy- 
momas. 
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